In a study with 51 HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapy, the pretreatment initial enhancement ratio, defined as the percentage signal increase relative to the baseline at the first postcontrast acquisition, was not associated with tumor pathological complete response after treatment.294 Therefore, the changes in the DCE-MRI parameters of tumors after treatment may better reflect the impact of trastuzumab on tumors and serve as a more helpful tool for evaluating treatment efficacy. This evidence concerns the gene ERBB2 and breast carcinoma.